WASHINGTON, Dec. 17 /PRNewswire-USNewswire/ -- The Advanced Medical Technology Association (AdvaMed) announced today that it has established a new division - AdvaMed Dx - to focus solely on issues facing companies that manufacture in vitro diagnostic technologies. The division will function as an association within an association, while still having access to, and support from, the broader resources offered by AdvaMed.
AdvaMed Dx will be governed by an 18-member Board of Directors and an 8-member Executive Committee, comprised of CEOs from in vitro diagnostics companies. The Board of Directors will be chaired by Scott Garrett, Beckman Coulter’s chairman, president and chief executive officer. Full-time staff will include an executive director and a director of communications that will be located in AdvaMed’s offices and have access to the full complement of AdvaMed’s policy expertise and other resources.
Some of the issues of particular importance that AdvaMed Dx will focus on include establishment of a modernized risk-based approach to the regulation of in vitro diagnostics to support timely patient access to safe and effective tests. It will also focus on reforming the antiquated Medicare payment system for clinical laboratory diagnostic tests to fully recognize the value of new tests, especially the new generation of molecular diagnostic tests.
CONTACT: Wanda Moebius, +1-202-434-7240
Web site: http://www.advamed.org/
